tert-Butyl 3-(4-hydroxy-2-methylphenyl)propanoate | 591777-17-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: tert-Butyl 3-(4-hydroxy-2-methylphenyl)propanoate
• CAS: 591777-17-2
• 化学式: C₁₄H₂₀O₃
• 分子量: 236.311
• InChiKey: FDNPWMMNZZYGKY-UHFFFAOYSA-N

物化性质

• 沸点：
  346.0±27.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-Butyl 3-(4-hydroxy-2-methylphenyl)propanoate 在 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 3-[4-[3-[(6-Chloro-1,3-benzothiazol-2-yl)-(thiophen-2-ylmethyl)amino]propoxy]-2-methylphenyl]propanoic acid
  参考文献：
  名称：

  Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARδ-selective agonists

  摘要：

  To find novel PPAR delta-selective agonists, we designed and synthesized phenylpropanoic acid derivatives bearing 6-substituted benzothiazoles. Optimization of this series led to the identification of a potent and selective PPAR delta agonist 17. Molecular modeling suggested that compound 17 occupies the Y-shaped pocket of PPAR6 appropriately. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.017
• 作为产物：
  描述：

  4-溴-3-甲基苯酚 在 palladium diacetate 、 palladium on activated charcoal 氢气 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 甲醇 为溶剂， 生成 tert-Butyl 3-(4-hydroxy-2-methylphenyl)propanoate
  参考文献：
  名称：

  Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARδ-selective agonists

  摘要：

  To find novel PPAR delta-selective agonists, we designed and synthesized phenylpropanoic acid derivatives bearing 6-substituted benzothiazoles. Optimization of this series led to the identification of a potent and selective PPAR delta agonist 17. Molecular modeling suggested that compound 17 occupies the Y-shaped pocket of PPAR6 appropriately. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.017

文献信息

• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DU PROLIFERATEUR DES PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2003072100A1

  公开（公告）日：2003-09-04

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: (Formula I); wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, aryl (C0-C4) alkyl, aryloxy (C0-C4) alkyl, arylthio (C0-C4) alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C1-C5 alkyl, C1-C5 alkenyl, and arylC0-C3alkyl; (c) T1 is selected from the group consisting of C and N; (d) W is selected from the group consisting of CH2, C(O)N(R21), N(R21), N(R21)CH2, O, OCH2, S, and SO2; and(e) X is selected from the group consisting of C, CH2C, and CCH2.

  本发明涉及以下结构式所表示的化合物及其药学上可接受的盐，公式I：（公式I）;其中：（a）R5选自（C1-C6）烷基，（C1-C6）烯基，芳基（C0-C4）烷基，芳氧基（C0-C4）烷基，芳硫基（C0-C4）烷基，进一步地，当R5是烷基时，R5可以选择与W结合形成一个6元环杂环烷基环，该环与R5基固定的噁唑或噻唑环融合；（b）R9选自C1-C5烷基，C1-C5烯基和芳基C0-C3烷基；（c）T1选自C和N的群；（d）W选自CH2，C（O）N（R21），N（R21），N（R21）CH2，O，OCH2，S和SO2的群；（e）X选自C，CH2C和CCH2的群。
• Peroxisome proliferator activated receptor modulators
  申请人：Conner Eugene Scott

  公开号：US20050107449A1

  公开（公告）日：2005-05-19

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the group consisting of (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, aryl (C 0 -C 4 ) alkyl, aryloxy (C 0 -C 4 ) alkyl, arylthio (C 0 -C 4 ) alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C 1 -C 5 alkyl, C 1 -C 5 alkenyl, and arylC 0 -C 3 alkyl. (c) T 1 is selected from the group consisting of C and N, (d) W is selected from the group consisting of CH 2 , C(O)N(R21), N(R21), N(R21)CH 2 , O, OCH 2 , S, and SO 2 ; and (e) X is selected from the group consisting of C, CH 2 C, and CCH 2

  本发明涉及由以下结构式表示的化合物及其药学上可接受的盐，式I（式I）; 其中：（a）R5选自由（C1-C6）烷基，（C1-C6）烯基，芳基（C0-C4）烷基，芳氧基（C0-C4）烷基，芳硫基（C0-C4）烷基组成的群体，此外，当R5为烷基时，R5可以选择性地与W结合，形成与R5基固定的噁唑或噻唑环融合的6元环杂环烷基环; （b）R9选自由C1-C5烷基，C1-C5烯基和芳基C0-C3烷基组成的群体；（c）T1选自由C和N组成的群体；（d）W选自由CH2，C（O）N（R21），N（R21），N（R21）CH2，O，OCH2，S和SO2组成的群体；（e）X选自由C，CH2C和CCH2组成的群体。
• PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1480642B1

  公开（公告）日：2008-11-26
• US7153878B2
  申请人：——

  公开号：US7153878B2

  公开（公告）日：2006-12-26
• US7259175B2
  申请人：——

  公开号：US7259175B2

  公开（公告）日：2007-08-21